...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
【24h】

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.

机译：omalizumab在严重持续性过敏性哮喘患者中的成本效益。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real-life studies that assess the effectiveness of treatment are of particular interest. Methods: We determined the incremental cost-effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from the real-life 1-year randomized open-label study (ETOPA) and using Canada as a reference country. Only patients receiving high-dose ICS plus LABA were included in the analysis, reflecting the EU label for omalizumab. Costs and quality-adjusted life years (QALYs) gained were used to calculate the ICER for omalizumab (cost/QALY). Probabilistic sensitivity analysis was performed to determine the 95% confidence interval and one-sided sensitivity analyses were performed. Results: The base case lifetime analysis of standard therapy vs standard therapy plus add-on omalizumab for the first 5 years, gave an ICER of euro31 209. Probabilistic sensitivity analysis indicated that the 95% confidence interval around the ICER was euro27 739-euro40 840. The ICER range for one-way sensitivity analyses was euro23 762 without discounting to euro66 443 without inclusion of asthma-related mortality. Conclusions: This study demonstrates that add-on omalizumab therapy is cost-effective in patients with severe persistent allergic asthma.
机译：背景：哮喘的健康，经济和社会负担相当可观，在患有严重哮喘的患者中尤其是在控制不充分时尤其严重。评估治疗效果的现实生活研究尤为重要。方法：我们使用来自真实生活的1年随机开放标签研究（ETOPA）的数据，并以加拿大作为参考国家，确定了将奥马珠单抗加入标准治疗的增量成本效益比（ICER）。分析中仅包括接受大剂量ICS加LABA的患者，这反映了奥马珠单抗的EU标签。使用获得的成本和质量调整生命年（QALYs）来计算奥马珠单抗的ICER（成本/ QALY）。进行概率敏感性分析以确定95％置信区间，并进行单方面敏感性分析。结果：标准治疗与标准治疗加上附加奥马珠单抗的前5年基本病例生命周期分析得出的ICER为euro31209。概率敏感性分析表明，ICER周围的95％置信区间为euro27 739-euro40 840单向敏感性分析的ICER范围为euro23 762，不折算为euro66 443，不包括与哮喘相关的死亡率。结论：这项研究表明，对于严重的持续性过敏性哮喘患者，加用奥马珠单抗治疗具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号